-
Targeting SUMOylation in Cholangiocarcinoma: A Potential Therapeutic Approach
A recent study published in Hepatology explores the role of SUMOylation in cholangiocarcinoma (CCA) and its potential as a therapeutic target. The research analyzed tumors from multiple patient cohorts and…
-
ESMO 2024丨Early Immunotherapy Significantly Extends Overall Survival in Triple-Negative Breast Cancer Patients
The final results of the KEYNOTE-522 trial confirm the potential of pembrolizumab to change patient management, though careful patient selection and toxicity monitoring are essential.
-
ILCA 2024丨Dr. Tao Peng: New Therapy for Early Multinodular Liver Cancer — Promising Results from Cadonilimab Combined with FOLFOX-HAIC
Editor’s Note: Primary hepatocellular carcinoma (HCC) is a prevalent malignant tumor, and combining systemic therapy, immunotherapy, and regional local treatment is guiding HCC clinical treatment to new heights. At the recent 18th International Liver Cancer Association (ILCA) Annual Meeting, Dr. Tao Peng from the Hepatobiliary Surgery Department of The First Affiliated Hospital of Guangxi Medical…
-
AOS 2024: Uniting Asia in the Fight Against Cancer
On November 15, 2024, the 4th International Congress of the Asian Oncology Society (AOS 2024) opened in Xi’an, China, co-hosted by the Chinese Anti-Cancer Association and the Asian Oncology Society. Under the theme “Integration and Modernity,” the conference brought together leading oncology experts from across Asia and the globe, fostering academic collaboration and advancing cancer…
-
2024 CCHIO & CACA 40th Anniversary: A Landmark Event in Cancer Prevention and Treatment
On November 14, 2024, the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) and the 40th Anniversary of the China Anti-Cancer Association (CACA) commenced at the Xi’an International Conference Center. Themed “CACA at 40: Carrying Forward and Innovating,” the event brought together medical experts, patient advocates, and leaders from various sectors to advance the fight…
-
Exploring Icosabutate for MASH: Insights from a Phase IIb Trial
A recent phase IIb randomized trial, published in the Journal of Hepatology, evaluated Icosabutate, an oral FFAR1/FFAR4 agonist, in patients with biopsy-confirmed MASH and fibrosis (F1-F3). While the primary endpoint…
-
Advancing HCC Treatment: The Potential of Salsalate with Lenvatinib
New research in JHEP Reports explores how Salsalate, a rheumatoid arthritis therapy, may enhance the effectiveness of Lenvatinib in treating MASH-driven hepatocellular carcinoma (HCC). By stimulating AMPK, enhancing fatty acid…
-
Immune Dysfunction and Infection Risk in Advanced Liver Disease
The latest review in Gastroenterology explores the complex relationship between immune dysfunction and infection risk in advanced liver disease, highlighting the contributions of Brett McGettigan, Maria Hernandez-Tejero, Harmeet Malhi, and…
Connecting Medical Expertise through Media